Outcomes of children treated for multiple Epstein–Barr virus‐associated post‐transplant tumors

Abstract

AbstractBackgroundAfter solid organ transplantation, children are at risk for Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorder and smooth muscle tumors. Little is known about the clinical course, Epstein–Barr viral load variations, and optimal treatment for such patients. We set forth to understand the course of repeated episodes of post‐transplant lymphoproliferative disorder and smooth muscle tumors.MethodsWe performed a retrospective chart review of patients up to 21 years old with solid organ transplantation and post‐transplant lymphoproliferative disorder at the Children's Hospital of Philadelphia from January 2003 through June 30, 2020.ResultsSix patients had multiple episodes of Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorder and smooth muscle tumors. When the second episode was discovered, only one patient was symptomatic. Histology differed from diagnosis in four patients. Treatment included viral‐specific T‐lymphocytes (2), rituximab (3), reduction in immunosuppression alone (1). Five patients had complete response, and one had stable disease, but three patients developed a subsequent tumor. Two patients developed Epstein–Barr virus‐associated smooth muscle tumors. Of these six patients, four are alive. The deaths were not related to their tumors.ConclusionsDespite a complete response to initial therapy, children are at risk for repeated episodes of Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorder and smooth muscle tumors. Histology and location were not typically consistent with initial diagnosis, suggesting these are second primaries rather than recurrences. Disease may be managed with individualized treatment plans but EBV‐specific T cells need further study in such tumors.